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Open access under CC BY-NC-ND license. Summary Objectives: Comparisons of procalcitonin (PCT), C-reactive protein (CRP), and sol-
uble triggering receptor expressed on myeloid cells-1 (sTREM-1) would expand our knowledge
of which biomarker is the best predictor for outcomes of patients with pulmonary tuberculosis
(PTB).
Methods: We prospectively enrolled 243 PTB patients, in whom PCT, CRP, and sTREM-1 mea-
surement were performed to evaluate their prognostic value for 6-month mortality.
Results: Serum PCT, CRP, and sTREM-1 levels on diagnosis of PTB were significantly higher in
nonsurvivors (2.22  6.22 vs. 0.13  0.31 ng/mL, P Z 0.043; 42.1  59.4 vs.
12.5  29.1 mg/L, P Z 0.004; 332  362 vs. 128  98 pg/mL, P Z 0.001, respectively) as
compared with 6-month survivors. In multivariate Cox regression analysis, PCT S0.5 ng/mL
(hazard ratio 4.13, 95% CI, 1.99e8.58) and sTREM-1 S129 pg/mL (hazard ratio 3.39, 95% CI,
1.52e7.58) remained independent mortality predictors. Serum PCT and sTREM-1 levels above
the cutoffs were also associated with the presence of disseminated tuberculosis.of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100,
886 2 23582867.
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PCT, CRP, and sTREM-1 in pulmonary tuberculosis 441Conclusions: Among PTB patients, higher PCT, CRP, and sTREM-1 levels are observed in nonsur-
vivors than in 6-month survivors. Serum levels of PCT and sTREM-1 over the cutoffs are inde-
pendently associated with a poor outcome. In addition, higher PCT and sTREM-1 levels
would raise the clinical suspicion of disseminated tuberculosis.
ª 2014 The Authors. Published by Elsevier Ltd on behalf of the The British Infection Associa-
tion.Open access under CC BY-NC-ND license. Introduction
Tuberculosis (TB) remains a major public health concern
worldwide, with an estimated 1.3 million deaths reported
in 2007. The disease is concentrated in the developing
world and 80% of all cases are present in the highest-burden
countries. Despite technological developments over the
past 100 years, the diagnostic tools for TB are similar to
those used a century ago, particularly in low-income
countries. Throughout the past decade, a number of
biomarkers have been tested for the diagnosis of TB and
prognosis prediction in TB patients.
Procalcitonin (PCT) is a peptide consisting of 116 amino
acids that is synthesized in the thyroid gland and by the
leukocytes.1 It has been reported as a sensitive biomarker
of severe bacterial infection,2 and may help discriminate
between pulmonary TB (PTB) and bacterial pneumonia
because PCT does not appear to be significantly elevated
in PTB patients.3,4 With the usual cutoff of 0.5 ng/mL,
most patients with PTB have PCT levels below the upper
limit of normal.3,5 In addition, PCT can provide prognostic
information and may be helpful in identifying patients hav-
ing disseminated TB.4,5
C-reactive protein (CRP) is an acute-phase protein
widely used as a biomarker of inflammation and tissue
injury. A number of studies provided evidence for the
application of pleural CRP as a diagnostic aid in TB among
lymphocyte-predominant exudative effusion.6 Moreover,
serum CRP levels significantly differed in patients with
PTB and those with bacterial pneumonia,7 and positively
correlated with the degree of disease activity in PTB.4
The triggering receptor expressed on myeloid cells-1
(TREM-1) is a glycoprotein of the immunoglobulin superfam-
ily and is specifically expressed on the surfaces of mono-
cytes/macrophages and neutrophils.8 Its expression is
increased in infectious diseases and is associated with the
release of its soluble form, named sTREM-1, into the blood-
stream and body fluid.9 Compared with bacterial or fungal
infection, in which sTREM-1 is evidently upregulated, its
role during mycobacterial infection remains debatable.10
While early studies indicated that the presence of mycobac-
teria does not lead to upregulation of sTREM-1,8,11 subse-
quent works demonstrated contradictory findings.10,12
Further, pleural sTREM-1 may have a role in differentiating
pleural effusion due to bacterial and TB infection.13,14
Although each of the three biomarkers delivers some
useful information for PTB patients, a direct comparison of
them would further expand our knowledge. We, therefore,
conducted the present study to measure serum PCT, CRP,
and sTREM-1 levels to compare their clinical informative
value in the prediction of an unfavorable outcome and
disease extent in patients with PTB.Materials and methods
Study population
From June 2009 to December 2010, patients aged 20 years or
older and diagnosed with culture-confirmed PTB in the
National Taiwan University Hospital (NTUH) and NTUH, Yun-
Lin Branchwere prospectively enrolled in this study. Culture-
confirmed PTB was defined as Mycobacterium tuberculosis
(MTB) isolated from sputum samples with the presence of
new radiographic pulmonary infiltrates. Patients with HIV
infection orwith concomitant infectionwithpathogens other
than MTB were excluded from the study. PTB patients were
considered to have disseminated TB if they had concomitant
TB infection ofS2 non-contiguous organs15; thus, pleural TB
was considered a loco-regional disease rather than dissemi-
nated infection. Acid-fast smears and mycobacterial cul-
tures of the sputum samples were performed as previously
described.16 All PTB patients received a standard 4-drug
regimen consisting of daily isoniazid, rifampicin, etham-
butol, and pyrazinamide (HREZ) in the 2-month intensive
phase and daily HRE in the subsequent continuation phase.
Ethambutol might be omitted if the drug susceptibility
testing revealed an isoniazid- and rifampicin-susceptible
strain. This study was approved by the Research Ethics Com-
mittee of the NTUH and written informed consent was ob-
tained from all patients.
Blood sampling and measurement of PCT, CRP, and
sTREM-1
Peripheral blood was collected from patients when the
diagnosis of PTB was established. Serum was obtained by
centrifugation of the blood samples at 3000 rpm for 15 min
at 4 C and then frozen at 20 C until assay. PCT was
measured by Elecsys BRAHMS PCT electrochemilumines-
cence immunoassay (BRAHMS Diagnostica, Berlin, Ger-
many). The normal range of PCT is <0.5 ng/mL. CRP was
determined by CRP-Latex (II) SEIKEN High Sensitivity Assay
(Denka Seiken Co., Tokyo, Japan) with a normal range of
<5 mg/L. The levels of serum sTREM-1 were measured using
the enzyme-linked immunosorbent assay (Human TREM-1
Quantikine ELISA Kit; R&D Systems, Minneapolis, MN). The
technicians performing the assays were blinded as to the
clinical status of the patients. All of the tests were
performed in duplicate.
Data collection
On the diagnosis of PTB, the following items were recorded
for each patient: demographics, body mass index, smoking
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consumption of more than or equal to 60 g), prior history of
TB, comorbidities, blood tests, microbiologic results, and
radiographic findings. Chest radiographs were interpreted
by two board-certified pulmonologists blinded to clinical
parameters and treatment outcomes. The radiographic
extent of disease was classified as minimal, moderately
advanced, and far advanced based on the classification of
the National Tuberculosis and Respiratory Disease Associa-
tion.17 If there was discordance, it was resolved by
consensus. The primary outcome of interest was all-cause
mortality within 6 months and other outcomes investigated
included 2-month mortality and sputum culture conversion
at 2 months. All patients were followed up for 6 months af-
ter the diagnosis of PTB was made, or until death or loss to
follow-up.
Statistical analysis
Data were presented as mean  standard deviation or
number (percentage) of patients. Comparisons between
groups were done using a c2 test or Fisher’s exact test for
categoric variables and the Student’s t-test for continuous
variables. The discriminative power of PCT, CRP, and
sTREM-1 for 6-month mortality was assessed through
comparing areas under receiver operating characteristic
(ROC) curves using the Stata Version 10.0 (Stata Co.,Table 1 Characteristics of 6-month survivors and nonsurvivors
Characteristics Total (n Z 243) S
Age, years 62.1  17.9 6
Male sex 164 (68) 1
Body mass index 21.4  3.2 2
Current smoker 45 (19) 4
Alcoholism 14 (6) 1
Past history of tuberculosis 17 (7) 1
Comorbidities
Malignancy 50 (21) 3
Diabetes mellitus 49 (20) 3
Renal dysfunction 32 (13) 2
Obstructive lung disease 29 (12) 2
Laboratory testing
Leukocyte count, mL 8320  3828 8
Albumin, g/dL 3.4  0.5 3
Total bilirubin, mg/dL 0.8  0.7 0
Microbiology
Positive sputum acid-fast smear 132 (54) 1
Mono-drug resistant tuberculosisa 35 (14) 3
Radiographic findings
Extent of disease
Minimal 77 (32) 6
Moderately advanced 133 (55) 1
Far advanced 33 (14) 2
Cavitary lesion 36 (15) 2
Pleural effusion 70 (29) 5
Disseminated tuberculosis 23 (10) 1
Data are presented as mean  standard deviation or number (percen
a No patients with multidrug-resistant tuberculosis included in thisCollege Station, TX). The optimal cutoff for predicting mor-
tality was determined by the least squares method. The pa-
tients were dichotomized into two groups based on the
upper limit of normal or the optimal cutoff if the former
was not available. Cox proportional hazards models were
used to identify the predictors of 6-month mortality in uni-
variate and multivariate analyses. All potential predictors
with a P value of <0.1 in the univariate analysis were
entered into the multivariate model. Survival curves were
plotted using the KaplaneMeier method and compared
with the log-rank test. Statistical significance was defined
at a two-tailed P value of <0.05. The statistical analyses
were performed using the SPSS Version 15.0 (SPSS Inc., Chi-
cago, IL) and Stata Version 10.0 software packages.Results
Patients
A total of 243 patients (164 males, 62.1  17.9 years) were
prospectively enrolled in this study. The baseline charac-
teristics, comorbidities, laboratory data, and microbiologic
and radiographic features are outlined in Table 1. Among
them, 132 (54%) patients were sputum acid-fast smear-pos-
itive and 35 (14%) had mono-drug resistant tuberculosis.
Chest radiographs showed the presence of cavity andamong patients with pulmonary tuberculosis.
urvivors (n Z 204) Nonsurvivors (n Z 39) P value
0.3  18.0 71.2  14.5 <0.001
34 (66) 30 (77) 0.195
1.4  3.0 21.0  4.0 0.459
0 (20) 5 (13) 0.376
1 (5) 3 (8) 0.572
2 (6) 5 (13) 0.120
8 (19) 12 (31) 0.128
8 (19) 11 (28) 0.192
6 (13) 6 (15) 0.655
6 (13) 3 (8) 0.372
096  3462 9493  5255 0.118
.5  0.5 3.1  0.7 0.001
.8  0.6 1.0  0.8 0.153
08 (53) 24 (62) 0.382
0 (15) 5 (13) 1.000
5 (32) 12 (31) 0.375
14 (56) 19 (49)
5 (12) 8 (21)
6 (13) 10 (26) 0.038
3 (26) 17 (44) 0.026
7 (8) 6 (15) 0.168
tage) of patients.
study.
Figure 1 Boxplot showing procalcitonin (A), C-reactive pro-
tein (B), and soluble triggering receptor expressed on myeloid
cells-1 (sTREM-1) (C) levels on the diagnosis of pulmonary
tuberculosis in 6-month survivors and nonsurvivors.
Figure 2 Receiver operating characteristic plot analysis for
prediction of 6-month using procalcitonin, C-reactive protein,
and soluble triggering receptor expressed on myeloid cells-1
(sTREM-1) levels in patients with pulmonary tuberculosis.
AUC, area under the curve.
PCT, CRP, and sTREM-1 in pulmonary tuberculosis 443pleural effusion in 36 (15%) and 70 (29%) patients, respec-
tively. More than half (55%) of the patients had radiographic
findings of moderately advanced disease, and far advanced
disease was observed in only 14% of the patients. Dissemi-
nated TB was diagnosed in 23 (10%) patients.
Overall, 39 (16%) patients died within 6 months after the
diagnosis of PTB. The causes of death were multi-organ
failure (n Z 19), progressive respiratory failure (n Z 11),
acute myocardial infarction (n Z 2), massivegastrointestinal bleeding (n Z 2), hepatic failure (n Z 2),
malignancy (n Z 2), and heart failure (n Z 1). Univariate
analysis revealed that the mortality was associated with
older age, a lower serum albumin level, and the presence
of cavitary lesion and pleural effusion on chest radiographs
(Table 1). There was no difference in sex, body mass index,
habits of smoking and drinking alcohol, comorbidities,
microbiology, and other blood testing results between non-
survivors and survivors.Serum PCT, CRP, and sTREM-1 levels
In PTB patients, mean serum levels of PCT, CRP, and sTREM-
1 were 0.47  2.60 ng/mL, 17.3  37.2 mg/L, and
161  185 pg/mL, respectively. Twenty-seven (11%) pa-
tients had PCT levels exceeding the normal cutoff value of
0.5 ng/mL and 105 (43%) had serum levels of CRP above the
upper limit of normal of 5 mg/L. The PCT, CRP, and sTREM-1
levels on the diagnosis of PTB were higher in patients who
died within 6 months (PCT: 2.22  6.22 vs. 0.13  0.31 ng/
mL, P Z 0.043; CRP: 42.1  59.4 vs. 12.5  29.1 mg/L,
P Z 0.004; sTREM-1: 332  362 vs. 128  98 pg/mL,
P Z 0.001). Fig. 1 displays serum levels of PCT, CRP, and
sTREM-1 in 6-month survivors and nonsurvivors.Predictive value of PCT, CRP, and sTREM-1 for 6-
month mortality
To assess the potential of the three biomarkers to predict 6-
month mortality, ROC curves were plotted (Fig. 2). The
analysis identified the areas under the curves (AUCs) of
0.79 (95% confidence interval [CI], 0.71e0.87), 0.75 (95%
CI, 0.67e0.83), and 0.76 (95% CI, 0.68e0.84) for PCT,
CRP, and sTREM-1, respectively. Of note, the predictive po-
tential of the three biomarkers was comparable
(P Z 0.571). The best calculated cutoff values for PCT,
CRP, and sTREM-1 were 0.06 ng/mL, 2.38 mg/L, and
129 pg/mL for the prediction of 6-month mortality
(Table 2). Using the upper limit of normal of 0.5 ng/mL
for PCT and 5 mg/L for CRP, the sensitivity was 41.0% and
Table 2 The C-reactive protein, procalcitonin, and sTREM-1 test characteristics at different cutoffs for the prediction of 6-
month mortality.
Sensitivity, % Specificity, % Likelihood ratio, þ/
Procalcitonin, ng/mL
S0.03 94.9 23.0 1.23/0.22
S0.06b 87.2 56.9 2.02/0.23
S0.15 56.4 80.9 2.95/0.54
S0.5a 41.0 94.5 7.45/0.62
C-reactive protein, mg/L
S0.60 94.9 28.4 1.33/0.18
S2.38b 89.7 52.5 1.89/0.20
S5.00a 69.2 62.0 1.82/0.50
S12.36 48.7 79.4 2.37/0.65
sTREM-1, pg/mL
S74 94.9 28.4 1.33/0.18
S109 82.1 54.9 1.82/0.33
S129b 79.5 66.2 2.35/0.31
S175 48.7 79.4 2.37/0.65
sTREM-1, soluble triggering receptor expressed on myeloid cells-1.
a Upper limit of normal.
b The best cutoff determined by the least squares method in receiver operating characteristic curve analysis.
444 C.-T. Huang et al.69.2%, and the specificity was 94.5% and 62.0%,
respectively.
Higher PCT, CRP, and sTREM-1 levels as well as age, a
lower albumin level, and the presence of cavitary lesion
and pleural effusion were associated with 6-month mor-
tality in the univariate Cox proportional hazards model
(Table 3). In multivariate regression analysis, only PCT,
sTREM-1, and albumin levels remained independently
associated with 6-month mortality. With a cutoff of
0.5 ng/mL serum PCT, patients with S0.5 ng/mL had
significantly shorter survival than those with <0.5 ng/mL
(Fig. 3A). Similarly, patients with a serum sTREM-1 level
of 129 pg/mL or above had significantly poor prognosis
(Fig. 3B). Table 4 shows the characteristics of patients
with dichotomous levels of PCT (S0.5 vs. <0.5 ng/mL)
and sTREM-1 (S129 vs. <129 pg/mL). Patients with PCT
S0.5 ng/mL or sTREM-1 S129 pg/mL were more likely
to have disseminated TB and to die within 2 or 6 months.
Table 5 shows the dichotomous levels of PCT and sTREM-1Table 3 Prediction of 6-month mortality in univariate and mul
Predictor Hazard ratio
Univariate analysis
Age, each year 1.04
Albumin, decrease of 1 g/dL 3.02
Cavitary lesion 2.14
Pleural effusion 2.06
C-reactive protein, S5 mg/L 3.25
Procalcitonin, S0.5 ng/mL 8.46
sTREM-1, S129 pg/mL 5.60
Multivariate analysis
Albumin, decrease of 1 g/dL 1.68
Procalcitonin, S0.5 ng/mL 4.13
sTREM-1, S129 pg/mL 3.39
CI, confidence interval; sTREM-1, soluble triggering receptor expressein each cause of death. Because of limited patient num-
ber, only patients succumbed to multi-organ failure and
progressive respiratory failure could be analyzed. We
observed that sTREM-1 S129 pg/mL seemed to be better
at predicting mortality due to multi-organ failure than
PCT S0.5 ng/mL.Discussion
In this prospective study of 243 patients diagnosed with
PTB, we compared the potential of serum PCT, CRP, and
sTREM-1 levels to predict an unfavorable outcome for PTB
patients. We report five major findings. First, a significant
proportion of patients with PTB had serum CRP levels above
the normal cutoff; however, serum levels of PCT above the
upper limit of normal were observed in only few PTB
patients. Second, PCT, CRP, and sTREM-1 levels on the
diagnosis of PTB were significantly higher in 6-monthtivariate Cox proportional hazards models.
95% CI P value
1.02e1.07 0.001
1.98e4.61 <0.001
1.04e4.39 0.038
1.10e3.88 0.025
1.65e6.42 0.001
4.46e16.05 <0.001
2.66e11.79 <0.001
1.04e2.70 0.033
1.99e8.58 0.003
1.52e7.58 <0.001
d on myeloid cells-1.
Figure 3 Survival curves for dichotomous levels of procalci-
tonin (PCT) (A) and soluble triggering receptor expressed on
myeloid cells-1 (sTREM-1) (B) using the KaplaneMeier method
(both log-rank P < 0.001).
PCT, CRP, and sTREM-1 in pulmonary tuberculosis 445nonsurvivors than in survivors. Third, PCT, CRP, and sTREM-
1 exhibited comparable discriminative power in predicting
6-month mortality in patients with PTB. Fourth, higher PCT
and sTREM-1 levels and a lower albumin level were inde-
pendent associated with a poor 6-month outcome. Fifth, a
PCT level over the normal cutoff (0.5 ng/mL) and an sTREM-
1 level above the best cutoff (129 pg/mL) were also
associated with higher 2-month mortality and the presence
of disseminated TB.
It has been reported that sTREM-1 is poorly expressed in
pneumonia or pleuritis caused by TB compared with in thoseTable 4 Features and outcomes of pulmonary tuberculosis pat
variables.
Procalcitonin
S0.5 ng/mL <0.5 ng/mL
Total patients (n Z 243) n Z 27 n Z 216
6-month mortality 16 (59) 23 (11)
2-month mortality 10 (37) 8 (4)
Disseminated tuberculosis 7 (26) 16 (7)
Total patients (n Z 225)a n Z 17 n Z 208
2-month culture conversion 15 (88) 151 (73)
sTREM-1, soluble triggering receptor expressed on myeloid cells-1.
a Patients alive at 2 months.caused by bacteria.8,13,14,18 Although the reasons why the
TREM-1 response in TB is poor remain to be clarified, there
are two possible explanations. One is that TREM-1 expression
is strongly upregulated by extracellular bacteria; in contrast,
intracellular microorganisms, such as MTB, have no ef-
fect.11,19 The other is that ligation of TREM-1 leads to sus-
tained secretion of tumor necrosis factor-a, interleukin-1b,
interleukin-8, and monocyte chemotactic protein-1,11,19 but
not interferon-g, which is thought to be a principal mediator
ofmacrophageactivationand resistance to intracellular path-
ogens.20 Thus, TREM-1 is not expected to be significantly
increased in TB infection. However, serum sTREM-1 levels
were elevated and spanned a wide range in our study popula-
tion. This is consistent with a recent work, which reported
that sTREM-1 expression is upregulated in patients with both
bacterial pneumonia and PTB.10 Moreover, the present study,
for the first time, shows that sTREM-1 might serve as a clini-
cally useful prognosticbiomarker forPTBpatients. The results
presented here extend our knowledge about the application
of this biomarker in caring for patients with PTB.
Our results are in line with other studies showing that
PCT activity is relatively low in PTB.3e5,21 In this regard,
several studies have examined PCT as a diagnostic tool in
PTB and TB pleuritis and in differentiating causes of pneu-
monia.1,3,4,12,22 Of note, a couple of studies found normal
serum PCT levels in patients with PTB.23 The cascade of in-
flammatory cytokines released during infection may deter-
mine the intensity of PCT synthesis and release, thus
accounting for the differences seen in the levels of this
biomarker.24 Gendrel et al.25 determined that when infec-
tion is loco-regional or single-organ confined without a sys-
temic response of the inflammatory reaction, PCT is low or
moderately increased. The destructive property of MTB is
due to the defensive response of the host immune system
that develops in its own tissue.26 Thus, the increase in
PCT in PTB patients may be ascribed to the inflammatory
response and cytokines.
PCT has seldom been evaluated as a biomarker for
predicting mortality risk in patients with PTB. The potential
of PCT to predict a poor outcome in PTB patients observed
in this study is in agreement with two recent works.4,5 Both
studies and ours demonstrated that PCT levels exceed the
normal range in less than 15% of patients; however, they
can provide prognostic information for PTB patients. These
findings suggest that serum PCT may be measured in
selected cases of PTB to help identify patients at higher
risk of mortality.ients with procalcitonin and sTREM-1 levels as dichotomous
P value sTREM-1 P value
S129 pg/mL <129 pg/mL
n Z 99 n Z 144
<0.001 30 (30) 9 (6) <0.001
<0.001 15 (15) 3 (2) <0.001
0.007 15 (15) 8 (6) 0.012
n Z 84 n Z 141
0.250 62 (74) 104 (74) 0.993
Table 5 Dichotomized procalcitonin and sTREM-1 levels in each cause of death.
Causes of death (n Z 39) Procalcitonin sTREM-1 P valuea
S0.5 ng/mL <0.5 ng/mL S129 pg/mL <129 pg/mL
Multi-organ failure n Z 19 6 (32) 13 (68) 14 (74) 5 (26) 0.021
Progressive respiratory failure n Z 11 6 (55) 5 (46) 10 (91) 1 (9) 0.125
Acute myocardial infarction n Z 2 1 (50) 1 (50) 2 (100) 0 (0) NA
Massive gastrointestinal bleeding n Z 2 2 (100) 0 (0) 2 (100) 0 (0) NA
Hepatic failure n Z 2 0 (0) 2 (100) 1 (50) 1 (50) NA
Malignancy n Z 2 1 (50) 1 (50) 0 (0) 2 (100) NA
Heart failure n Z 1 0 (0) 1 (100) 1 (100) 0 (0) NA
sTREM-1, soluble triggering receptor expressed on myeloid cells-1; NA, Not applicable.
a The P value indicated the comparison between procalcitonin and sTREM-1 within a certain cause of death, and was calculated by
McNemar test.
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association with a lower serum albumin level and a greater
risk of mortality, even after adjusting for potentially con-
founding variables, such as age and radiographic manifesta-
tions. This result is in agreement with studies in TB patients
requiring intensive care or hospitalization.27,28 The present
study included both ambulatory and hospitalized patients;
thus, it broadened the generalizability of previous findings.
Disseminated TB is a potentially deadly form of TB
resulting from massive lymphohematogenous spread of
MTB. The clinical presentations of disseminated TB are
highly variable and nonspecific, and characteristic radio-
graphic features may not be seen.29 Further, its diagnostic
approach has not been standardized.30 Previous reports
demonstrated that patients with disseminated TB usually
have several abnormal laboratory findings, showing
elevated alkaline phosphatase and g-glutamyltransferase,
hyperferritinemia, and hypercalcemia.15 Our study found
an association between PCT levels over the normal cutoff
or sTREM-1 levels above the best cutoff and disseminated
TB. This implicates that measurement of serum PCT or
sTREM-1 should be considered in certain PTB patients,
where its positivity would raise the clinical suspicion of
disseminated TB.
In contrast to PCT, increased serum levels of CRP over
the upper limit of normal are not uncommonly seen in
PTB.3,5,7 In this study, no significant difference was
observed in the discriminative power of PCT, CRP, and
sTREM-1 for differentiating survivors and nonsurvivors in
the context of PTB after 6-month follow-up. However, after
controlling for confounders, CRP was no longer predictive
of mortality. Similarly, it has been shown in other studies
that serum CRP levels do not predict mortality in PTB
patients.4,5
A higher PCT or sTREM-1 level at PTB diagnosis is
associated with increased mortality. How could the knowl-
edge of baseline PCT or sTREM-1 influence clinical practice?
It is hardly possible to answer the question on the basis of
evidence-based medicine, but we suggest that these
patients should be closely monitored, undergo further
clinical and laboratory investigations to assess disease
extent and identify comorbidities, and receive sophisti-
cated organ support and possibly more efficacious anti-TB
therapy. Clearly, further studies will be required to clarify
these issues.This study has several limitations that merit attention.
First, we only measured PCT, CRP, and sTREM-1 levels on the
diagnosis of PTB, but did not follow their dynamic changes
after starting anti-TB treatment. The changing trends for
these biomarkers may further improve the prognostic value
in PTB patients. Second, the optimal cutoff of sTREM-1 found
in this study may not be replicated in future studies because
standardization of the sTREM-1 assays is not yet available.
Third, although our study included a relatively large number
of PTB patients, the majority had drug-susceptible TB and
HIV-positive patients were excluded. Thus, the prognostic
value of PCT and sTREM-1 remains to be determined in
multidrug-resistant or HIV-positive PTB patients. Fourth, the
present study included older patients than other studies31,32;
this may hinder the generalizability of our results to younger
PTB patients.
In conclusion, our study found significantly higher PCT,
CRP, and sTREM-1 levels in nonsurvivors than in survivors
among PTB patients. A serum level of PCTS0.5 ng/mL and
a serum level of sTREM-1 level S129 pg/mL on the
diagnosis of PTB are both independently associated with a
poor outcome at 6 months, and may be candidates for
identifying patients at higher risk of mortality. Further,
higher serum PCT and sTREM-1 levels raise the probability
of disseminated TB.
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